Monster Beverage Corporation (MNST) Stock Forecast
Data as of May 2, 2026Consumer Defensive · Current price $77.19 (+0.15%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Jan 14, 2026 | Peter Grom | UBS | $84.00 | +8.8% |
| Jan 5, 2026 | Chris Carey | Wells Fargo | $86.00 | +11.4% |
| Dec 12, 2025 | Matthew Smith | Stifel Nicolaus | $82.00 | +6.2% |
| Dec 3, 2025 | Andrew Strelzik | BMO Capital | $73.00 | -5.4% |
| Dec 3, 2025 | Michael Lavery | Piper Sandler | $85.00 | +10.1% |
| Dec 3, 2025 | Chris Carey | Wells Fargo | $83.00 | +7.5% |
| Dec 1, 2025 | Nik Modi | RBC Capital | $81.00 | +4.9% |
| Nov 7, 2025 | Dara Mohsenian | Morgan Stanley | $81.00 | +4.9% |
| Nov 4, 2025 | Kaumil Gajrawala | Jefferies | $79.00 | +2.3% |
| Oct 24, 2025 | Matthew Smith | Stifel Nicolaus | $78.00 | +1.0% |
| Oct 10, 2025 | Nik Modi | RBC Capital | $75.00 | -2.8% |
| Aug 8, 2025 | Nik Modi | RBC Capital | $68.00 | -11.9% |
| Aug 8, 2025 | Chris Carey | Wells Fargo | $73.00 | -5.4% |
| Aug 8, 2025 | Michael Lavery | Piper Sandler | $74.00 | -4.1% |
| Jun 12, 2025 | Dara Mohsenian | Morgan Stanley | $70.00 | -9.3% |
| May 23, 2025 | Bonnie Herzog | Goldman Sachs | $67.00 | -13.2% |
| Nov 1, 2024 | Steve Powers | Deutsche Bank | $61.00 | -21.0% |
| Aug 8, 2024 | Bonnie Herzog | Goldman Sachs | $63.00 | -18.4% |
| Aug 8, 2024 | Andrew Strelzik | BMO Capital | $54.00 | -30.0% |
| Aug 8, 2024 | Michael Lavery | Piper Sandler | $46.00 | -40.4% |
Top Analysts Covering MNST
MNST vs Sector & Market
| Metric | MNST | Consumer Defensive Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.23 | 2.55 | 2.41 |
| Analyst Count | 31 | 12 | 18 |
| Target Upside | +10.6% | +1188.8% | +14.9% |
| P/E Ratio | 39.79 | -7.45 | 31.19 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $8.92B | $9.21B | $9.45B | 18 |
| 2027-12-31 | $9.62B | $10.01B | $10.53B | 17 |
| 2028-03-31 | $2.43B | $2.52B | $2.58B | 4 |
| 2028-06-30 | $2.61B | $2.71B | $2.77B | 6 |
| 2028-09-30 | $2.67B | $2.77B | $2.83B | 9 |
| 2028-12-31 | $2.63B | $2.73B | $2.79B | 4 |
| 2029-03-31 | $2.33B | $2.42B | $2.47B | 6 |
| 2029-06-30 | $2.51B | $2.61B | $2.66B | 8 |
| 2029-09-30 | $2.61B | $2.71B | $2.77B | 5 |
| 2029-12-31 | $2.53B | $2.63B | $2.68B | 5 |
| 2030-12-31 | $12.69B | $13.20B | $13.74B | 13 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $2.11 | $2.25 | $2.43 | 10 |
| 2027-12-31 | $2.35 | $2.53 | $2.76 | 9 |
| 2028-03-31 | $0.62 | $0.65 | $0.67 | 3 |
| 2028-06-30 | $0.68 | $0.72 | $0.74 | 6 |
| 2028-09-30 | $0.70 | $0.74 | $0.76 | 5 |
| 2028-12-31 | $0.67 | $0.71 | $0.73 | 5 |
| 2029-03-31 | $0.58 | $0.61 | $0.63 | 4 |
| 2029-06-30 | $0.63 | $0.66 | $0.68 | 2 |
| 2029-09-30 | $0.69 | $0.72 | $0.74 | 2 |
| 2029-12-31 | $0.62 | $0.65 | $0.67 | 2 |
| 2030-12-31 | $3.48 | $3.66 | $3.86 | 6 |
Frequently Asked Questions
What is the analyst consensus for MNST?
The consensus among 31 analysts covering Monster Beverage Corporation (MNST) is Buy with an average price target of $83.92.
What is the highest price target for MNST?
The highest price target for MNST is $86.00, set by Chris Carey at Wells Fargo on 2026-01-05.
What is the lowest price target for MNST?
The lowest price target for MNST is $23.00, set by Kevin Grundy at Jefferies on 2021-10-13.
How many analysts cover MNST?
31 analysts have issued ratings for Monster Beverage Corporation in the past 12 months.
Is MNST a buy or sell right now?
Based on 31 analyst ratings, MNST has a consensus rating of Buy (2.23/5) with a +10.6% upside to the consensus target of $83.92.
What are the earnings estimates for MNST?
Analysts estimate MNST will report EPS of $2.25 for the period ending 2026-12-31, with revenue estimated at $9.21B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.